WVE — INITIATION OF COVERAGE

Wave Life Sciences Ltd. (NASDAQ: WVE) Singapore-incorporated, Cambridge MA-headquartered clinical-stage RNA medicines company.

Market cap $2.9B | Price $15.36 | Cash $602M | EV ≈$2.3B | Shares 187.7M Filed 10-K today (Feb 26, 2026). All financials are FY2025 actuals unless noted.

I. BUSINESS OVERVIEW

Wave Life Sciences develops RNA medicines using its proprietary PRISM platform — a stereopure oligonucleotide chemistry that controls the three-dimensional structure of RNA therapeutics at each backbone position. The company operates across five modalities: RNAi silencing (SpiNA), RNA editing (AIMers), antisense silencing, splicing modification, and bifunctional approaches. All liver-targeted programs use GalNAc conjugate delivery — simple subcutaneous injection, no lipid nanoparticles, no viral vectors.

Pipeline (5 clinical + 1 preclinical programs)

Revenue Model

Zero product revenue. 100% collaboration income from GSK (FY2025) and historically from Takeda (terminated Q4 2024).

The GSK collaboration (signed 2022, effective January 2023) provided $170M upfront ($120M cash + $50M equity investment at $4.68/share for 10.68M shares, giving GSK ≈5.7% ownership). (10-K line 1284.) Wave is eligible for up to $1.2B in development milestones and $1.6B in commercial milestones across up to 8 programs, plus tiered royalties into the low-teens percent of net sales. GSK's 4th program was selected in January 2026.

The Takeda Collaboration Agreement (effective April 2018) expired in Q4 2024. Its termination triggered recognition of remaining deferred revenue ($71.3M in FY2024), which is why FY2024 revenue spiked to $108.3M. (10-K line 6700.)

Revenue recognized over time as Wave performs R&D obligations. FY2025 collaboration revenue: $42.7M, all from GSK. Deferred revenue balance: $52.2M ($44.4M current, $7.8M long-term).

Key Distinction: RNA Editing

Wave demonstrated the first clinical A-to-I RNA editing for AATD with WVE-006. The 10-K states: "there are no RNA editing programs currently in clinical development for AATD other than WVE-006" (line 1501), though Korro Bio and AIRNA have preclinical RNA editing programs. The approach corrects a single base mutation in SERPINA1 mRNA using endogenous ADAR enzymes — no exogenous enzyme delivery required. Unlike DNA base editing (BEAM's approach), RNA editing is reversible, requires no permanent genomic changes, and avoids collateral bystander edits and indels. The trade-off: chronic dosing required (likely quarterly/semi-annually) vs. one-time treatment for gene editing.

II. FINANCIAL PROFILE

Three-Year Trajectory (FY2023-FY2025)

All figures from the consolidated financial statements in the 10-K filed Feb 26, 2026.

                        FY2023      FY2024      FY2025
                        ──────      ──────      ──────
Revenue                 $113.3M     $108.3M     $42.7M
  GSK                    ≈$113M*     $37.0M      $42.7M
  Takeda                  ≈$0.3M*    $71.3M      $0
  (* FY2023 breakdown approximate; 10-K MD&A confirms
     FY2024 GSK=$37.0M, Takeda=$71.3M)

R&D Expense             $130.0M     $159.7M     $182.8M
G&A Expense              $51.3M      $59.0M      $75.3M
Total OpEx              $181.3M     $218.7M     $258.1M

Loss from Operations    ($68.0M)    ($110.4M)   ($215.4M)
Net Loss                ($57.5M)    ($97.0M)    ($204.4M)
EPS (diluted)           ($0.54)     ($0.70)     ($1.21)
Wtd Avg Shares          106.1M      138.3M      168.6M

Operating Cash Flow     ($19.4M)    ($151.0M)   ($187.5M)

Cash & Equivalents      $204.1M*    $305.8M*    $605.9M*
  (* cash + restricted cash, per cash flow statement)
Cash & Equiv (B/S)                  $302.1M     $602.1M
Accumulated Deficit     ($1,024.9M) ($1,121.9M) ($1,326.2M)
Shares Outstanding       119.2M      153.0M      187.7M

Sources: Income statement (10-K lines 7896-7913), cash flow statement (lines 7982-8029), equity statement (lines 7930-7972), MD&A revenue detail (lines 6697-6709).

What the Numbers Show

Accelerating burn, but FY2023 was artificially low. FY2023 operating cash outflow was only $19.4M because $113.3M in collaboration revenue nearly offset expenses. When Takeda terminated and one-time revenue faded, the true cash burn surfaced: $151M (FY2024) and $188M (FY2025). R&D grew 41% over two years ($130M to $183M). G&A grew 47% ($51M to $75M). This is a company scaling into multi-program clinical development.

FY2024 revenue spike was a one-time Takeda termination event, not organic growth. Of the $108.3M FY2024 revenue, $71.3M (66%) came from recognizing remaining Takeda deferred revenue upon collaboration termination in Q4 2024. GSK revenue was only $37.0M. This is critical context: the apparent revenue "decline" from $108M to $43M is actually a $5.7M increase in GSK revenue ($37.0M to $42.7M) masked by the non-recurring Takeda windfall. (10-K lines 6697-6709.)

Dilution is significant. Shares outstanding went from 86.9M (end FY2022) to 187.7M (end FY2025) — a 116% increase in three years. The December 2025 public offering raised ≈$402.5M gross (≈$378M net) at approximately $19.00 per share (18.55M ordinary shares + 2.63M pre-funded warrants). (10-K lines 6874-6883.) ATM facility through Jefferies raised $94.6M. Lifetime capital raised: $2,076.7M ($1,450.5M equity offerings, $536.9M collaborations, $89.3M private placements). (10-K line 6868.)

SBC escalating: $9.8M (FY2023) to $13.1M (FY2024) to $25.0M (FY2025). Nearly doubled year-over-year. $47.1M in unrecognized option compensation with 2.37-year average vesting period remaining. (10-K lines 7937, 7951, 7965, 7987.)

Cash runway. The 10-K states: "We expect that our existing cash and cash equivalents will be sufficient to fund our operations for at least the next twelve months from the issuance date of these financial statements." (10-K line 6888.) Based on $602M cash and FY2025 burn of $188M, a simple calculation suggests ≈3.2 years of runway (into mid-2028), but the 10-K explicitly caveats that "We have based this expectation on assumptions that may prove to be incorrect." (10-K line 6890.) Actual runway will be shorter given increasing R&D obligations (see Section VII).

Capital Structure

No debt. No convertible notes. Simple equity structure with one complication: 3.9M Series A preferred shares held by SNBL (founder Ken Takanashi's company). These carry no voting rights but represent a potential conversion/liquidation preference.

III. COMPETITIVE POSITION

By Indication

Obesity (WVE-007, INHBE target) — CROWDED, DATA IS EARLY AND MODEST

The INHBE mechanism silences Inhibin Beta E to promote fat loss while preserving muscle mass. Preclinical data showed weight loss comparable to daily semaglutide from a single dose in DIO mice, with muscle preservation.

Phase 1 (INLIGHT) interim data (Dec 2025) at 240mg single dose, 32 subjects, mean baseline BMI ≈32 (10-K lines 530-547):

INLIGHT Phase 1 Results (Day 85, single 240mg dose)
                        WVE-007     Placebo     Placebo-adjusted
                        ───────     ───────     ────────────────
Visceral fat            -9.4%       -0.2%       -9.2%    (p=0.02)
Total body fat          -4.5%       -0.5%       -4.0%    (p=0.07 — NOT significant)
Lean mass               +3.2%       +2.3%       +0.9%    (p=0.01)
Total mass              —           —           -0.9%
Activin E reduction     -78% max, >75% sustained through Day 85

Important context: The total body fat reduction failed to reach conventional statistical significance (p=0.07). The 0.9% placebo-adjusted total mass decrease is modest compared to GLP-1 receptor agonists, which produce 12-17% total body weight loss in Phase 3 trials. Management characterizes this as "fat loss similar to GLP-1 at three months" — this refers to body composition direction (fat loss with lean preservation), not magnitude. The study enrolled subjects with BMI ≈32 (lower than typical obesity trials), which management notes may limit the observable effect. Higher doses (400mg, 600mg) and longer follow-up may show larger effects. Safety was clean: no discontinuations, no severe/serious TEAEs.

Direct INHBE competitors per 10-K (line 1481-1483): SIX companies with Phase 1/1b programs — Arrowhead, Rona Therapeutics, Vial, BaseCure Therapeutics, SanegeneBio, and Hengrui. Plus Alnylam and Innovent with preclinical INHBE programs, and iBio with a preclinical Activin E antibody. This is a crowded race in a massive market.

AATD (WVE-006, RNA editing) — FIRST-IN-CLASS RNA EDITING, BUT COMPETITIVE LANDSCAPE IS DEEP

Wave demonstrated first-in-human RNA editing for AATD. The approach corrects the Z-allele point mutation in SERPINA1 mRNA, potentially addressing both liver and lung manifestations simultaneously. No approved therapy exists for AATD liver disease. ≈200,000 Pi*ZZ patients in US+EU. (10-K line 588-589.)

Full competitive landscape per 10-K (lines 1501-1512):

Gene/base editing approaches to AATD:

• BEAM Therapeutics (BEAM-302) — Phase 1/2, DNA base editing. One-time treatment potential. (10-K line 1503)
• YolTech Therapeutics — Phase 1 investigator-initiated trial, DNA base editing. (10-K line 1503-1504)
• Tessera Therapeutics — Phase 1/2 initiating, prime editing. (10-K line 1506)
• CRISPR Therapeutics — Preclinical, prime editing. (10-K line 1507)
• Prime Medicine — Preclinical, prime editing. (10-K line 1507)
• Korro Bio — Preclinical, RNA editing. (10-K line 1502)
• AIRNA — Preclinical, RNA editing. (10-K line 1502)

Other AATD clinical programs:

• Arrowhead Pharmaceuticals / Takeda — Phase 3 for AATD LIVER disease. This is the most advanced program targeting AATD liver pathology, the same primary target as WVE-006. (10-K lines 1510-1512.) This is a material competitive threat that consensus underappreciates.
• Krystal Biotech (KB408) — Phase 1, redosable gene therapy targeting AATD lung disease specifically. (10-K line 1509)
• Mereo BioPharma — Phase 2 completed. (10-K line 1509-1510)
• Sanofi — Phase 2. (10-K line 1510)
• Augmentation therapy (Grifols, Takeda, CSL Behring) — five approved products. $2B+ market. Weekly IV, lung only. (10-K lines 1491-1499.)

DMD (WVE-N531, exon 53 skipping) — NICHE

Targets exon 53 skipping in dystrophin gene. NDA filing targeted 2026. Competing with Sarepta's Vyondys 53 (golodirsen, accelerated approval 2019) and NS Pharma's Viltepso (viltolarsen, accelerated approval 2020), plus Sarepta's Elevidys gene therapy. Importantly, the 10-K notes: "To date, no clinical benefit of Vyondys 53 or Viltepso has been established" (line 1525) — both competitors face confirmatory trial requirements. (10-K lines 1516-1537.)

Huntington's Disease (WVE-003) — HIGH RISK, GSK COLLABORATION

Allele-selective SNP3-targeting antisense oligonucleotide. Phase 1b/2a (SELECT-HD). HD drug development has been a graveyard — Ionis/Roche tominersen failed Phase 3. Wave's allele-selective approach differs from prior non-selective approaches. High scientific risk, high unmet need (≈30,000 US patients). (10-K lines 812-816.)

PNPLA3 Liver Disease (WVE-008) — EARLY, LARGE TAM

RNA editing approach for PNPLA3 I148M mutation driving MAFLD/MASH. 9M homozygous carriers in US+EU. (10-K line 681.) CTA filing targeted 2026. Very early stage. Differentiation: RNA editing restores normal PNPLA3 function rather than silencing it, which may preserve retinol metabolism and better address fibrosis, ballooning, and inflammation. (10-K lines 692-698.)

Platform Value

GSK selected a 4th program in January 2026, suggesting the platform continues to deliver hits. The collaboration structure (up to 8 programs, 3-year extension option) implies ongoing utility. However, GSK has never once mentioned Wave on an earnings call across 7 transcripts searched — the collaboration is invisible to GSK's $45B+ revenue base. Wave needs GSK far more than the reverse.

IV. MANAGEMENT & GOVERNANCE

Key Executives

• Paul Bolno, MD — CEO since 2020. Built the current pipeline strategy. Granted 165,000 share award Feb 5, 2026; sold 10,480 shares Feb 9 at $13.45 (tax withholding, not conviction sell).
• Kyle Moran — CFO. Granted 45,625 share award Feb 5, 2026; sold 3,588 shares Feb 9 at $13.45. Also received 273,750 options at $12.75 strike.
• Chandra Vargeese — Chief Technology Officer (PRISM platform architect). Sold 3,228 shares Feb 9.
• 317 full-time employees as of Dec 31, 2025. (10-K line 2920.)

Insider Ownership & Transactions

Zero open-market insider purchases (Form 4 code P) across entire filing history. All insider acquisitions are through awards (code A) or option exercises (code M). No insider has bought stock with their own money at market price.

Recent insider sales are all tax-related (code S following code A awards). These are mechanical, not directional. But the absence of any voluntary buying is notable for a stock with 16/16 Buy ratings.

Major Shareholders

• RA Capital (Peter Kolchinsky): 13.4% (25.5M shares, per Schedule 13D/A filed Dec 15, 2025). Board seat through Kolchinsky. The 13D amendment was triggered by dilution from the December 2025 offering, not by buying or selling.
• SNBL (Ken Takanashi): ≈3% through Series A preferred + ordinary shares. Board seat. Related party payments to SNBL jumped from $1.0M (FY2024) to $4.6M (FY2025) — a 4.6x increase with no specific disclosure on what drove it. (10-K lines 9460-9469.)
• GSK: ≈5.7% (10.68M shares from $50M equity investment at $4.68/share, January 2023). (10-K lines 1283-1286.)

Board Composition

7 directors. Singapore-incorporated company means proxy filings follow a different timeline (no DEF 14A available yet for FY2025).

Capital Stewardship: Grade B-

Positives:

• Successfully raised $2.08B lifetime to fund capital-intensive pipeline
• GSK collaboration brought $170M non-dilutive + validation
• December 2025 offering priced at ≈$19/share — a premium to trailing averages
• No debt, simple structure

Negatives:

• Shares more than doubled in 3 years (86.9M to 187.7M)
• ATM usage ($94.6M through Jefferies) creates persistent selling pressure
• SNBL related party payments increasing with no transparency
• SBC nearly doubled to $25M with $47M more to recognize
• No insider open-market purchases ever

V. FACTOR PROFILE

Regression Results (1-year, 250 trading days)

WVE FACTOR DECOMPOSITION
──────────────────────────────────────────────────

Multi-factor model (SPY, MTUM, XBI, IWM):

Factor          Beta        Variance Contribution
─────────────────────────────────────────────────────
SPY (market)    -2.49       -3.7%
MTUM (momentum) +1.57       +3.3%
XBI (biotech)   +1.32       +5.2%
IWM (small-cap) +0.69       +1.7%
Idiosyncratic    —          93.6%

R² = 6.4%    Alpha = +63.1% ann    Sigma_idio = 159.8%    n = 250

Note: R-squared of 6.4% means the factor model explains almost nothing — WVE is genuinely idiosyncratic. The "alpha" is essentially the raw return with minimal factor adjustment. With sigma_idio of 160%, the information ratio (alpha/sigma) is 0.39 — the alpha is wide because the vol is enormous.

Interpretation

This is overwhelmingly a company-specific bet. 94% idiosyncratic variance — the highest in the RNA therapeutics peer group by a wide margin.

Peer comparison (our regression analysis):

Ticker   %Idio    XBI Beta   Alpha (ann)   Sigma_idio   Verdict
─────────────────────────────────────────────────────────────────
WVE      93.6%    +1.32      +63.1%        159.8%       Pure company bet
PRME     74.3%    +1.98      +34.4%         98.4%       Mostly company
ALNY     76.2%    +0.54      +12.0%         38.0%       Mostly company
ARWR     61.3%    +1.41      +78.8%         56.5%       Mixed
IONS     63.5%    +1.24      +61.5%         40.8%       Mixed
BEAM     53.9%    +1.94      -45.0%         58.3%       Sector bet (failing)

Negative market beta (SPY beta = -2.49): Statistical artifact of idiosyncratic moves coinciding with down-market days, not a genuine defensive characteristic.

Positive momentum loading (+1.57): Natural accumulation from being a 1Y winner (+44.9%). At 3.3% variance contribution, manageable but will grow if trend continues.

Moderate biotech sector loading (+1.32, 5.2% variance): Despite meaningful beta to XBI, the sector explains almost nothing because WVE's own vol (160% annualized) dwarfs XBI moves (≈22% vol).

BEAM comparison is instructive: BEAM loads heavily on XBI (46.5% of variance from sector) with -45% company-specific alpha. BEAM is a sector bet destroying value at the stock-specific level. WVE is the opposite.

Sizing implication: With 94% idio, nearly all return is company-specific. Proportional sizing on alpha is clean — no need to hedge sector or market. But 160% annualized vol means modest position sizing. A 3% portfolio position generates +/-4.8% portfolio impact on a one-sigma daily move.

VI. FORWARD EXPECTATIONS GAP ANALYSIS

What $2.9B Market Cap Requires

Market cap:                         $2.9B
Less: cash                         ($602M)
Less: deferred revenue              ($52M)
Enterprise value:                   ≈$2.25B
Plus: PV of future burn (≈2.5yr)   +$450M    (our estimate based on $188M/yr)
Implied pipeline value:            ≈$1.8B

The market is paying ≈$1.8B for the pipeline net of cash and future burn. Decomposing across programs (our estimates, not sourced):

Note: These P(success) estimates are our reverse-engineering from market cap, not empirical base rates. Industry base rates for Phase 1 to approval run 7-12% across all indications, with genetically-validated targets somewhat higher. No drug targeting INHBE has ever been approved.

At current price, obesity is the dominant value driver — roughly half the implied pipeline value. AATD is second. Everything else is rounding error to the stock.

Street Estimates vs Filing Reality

16 analysts, all Buy/Overweight. Zero Holds, zero Sells. Median target $32.50 (+112%). Range $22-$50. 10.5% short interest despite unanimous bullish consensus — somebody is betting against.

                    Consensus       Filing Says (10-K)           Gap
─────────────────────────────────────────────────────────────────────
FY2025 Revenue      $43.0M          $42.7M (actual)            None
FY2026 Revenue      $49.9M          Timing issue (see below)   Quarterly
FY2025 EPS          -$1.20          -$1.21 (actual)            None
FY2026 EPS          -$1.26          Likely worse (see below)   Optimistic
Cash                $602M           $602.1M                    None

Five Specific Disconnects

1. FY2026 EPS consensus (-$1.26) is too optimistic.

Wave now bears 100% of WVE-006 development costs that GSK was contractually obligated to fund from pivotal onward. The 10-K (line 8615-8617) states GSK was to be "responsible for advancing WVE-006 through pivotal studies, registration, and global commercialization at GSK's sole cost." That obligation no longer exists. Additional 2026 cost drivers: WVE-008 CTA filing/clinical entry, WVE-N531 NDA preparation, Phase 2a multidose study for WVE-007, and higher SBC. Weighted average diluted shares will be ≈190-195M (vs 168.6M in FY2025). Our estimate: FY2026 EPS of -$1.35 to -$1.50.

2. Q1 2026 revenue will be lumpy.

The WVE-006 rights return (Feb 2, 2026) triggers accelerated recognition of AATD-allocated deferred revenue. The 10-K (line 8699) shows development milestone consideration was specifically allocated to the AATD Collaboration. A portion of the $52.2M deferred balance may accelerate into Q1 2026, creating a one-quarter revenue spike followed by lower run-rate quarters. Annual consensus of $49.9M may be roughly right in aggregate but miss the quarterly cadence.

3. WVE-006 100% ownership: the funding gap.

Analyst models assign full rNPV to WVE-006 with 100% economics. But commercializing a rare disease therapy through Phase 3 + NDA + launch typically requires $200-450M (our estimate; not sourced to a specific benchmark). With $602M cash and $188M/yr existing burn, self-funding WVE-006 to commercialization would require additional capital. Either Wave raises it (dilution), repartners (economics shared), or narrows the pipeline to fund it.

4. Options IV is cheap relative to near-term catalysts.

ATM IV at 98% sits at the 14th percentile of its 52-week range (41.9%-439.6%). Term structure is flat (near 98%, far 103%). Yet management disclosed imminent Q1 2026 data: 6-month 240mg data and 3-month 400mg data for WVE-007. These are significant data readouts for the stock's dominant value driver. The options market is not pricing a binary event.

5. Unanimity of sell-side coverage is itself information.

16/16 Buy ratings. Zero dissent. 10.5% short interest. When everyone on the sell side agrees and shorts remain, the consensus view may be fully priced. The risk is asymmetric to the downside on negative data — a miss on WVE-007 durability has nowhere to hide in consensus.

VII. KEY RISKS

Clinical/Scientific

1. WVE-007 durability and magnitude are unproven. The INLIGHT Phase 1 data showed 4.0% placebo-adjusted total fat mass reduction that failed conventional statistical significance (p=0.07). Total mass decrease was 0.9%. While visceral fat reduction was significant (9.2%, p=0.02) and lean mass preservation was demonstrated, the magnitude of weight/fat loss is far below GLP-1s (12-17% total body weight loss). Q1 2026 six-month data will show whether effects accumulate, sustain, or wane.

2. WVE-007 dose-response unclear. 240mg cohort showed the reported effect. 400mg cohort 3-month data coming Q1 2026. If higher dose doesn't meaningfully improve on 240mg, the therapeutic window may be narrow.

3. INHBE competitive density. Six companies have clinical-stage INHBE programs (Arrowhead, Rona, Vial, BaseCure, SanegeneBio, Hengrui), plus preclinical programs from Alnylam and others. (10-K line 1481-1483.) This is not a first-mover situation for INHBE.

4. WVE-006 accelerated approval path unproven. Wave plans to engage FDA on accelerated approval using surrogate endpoints (AAT protein levels). FDA has not agreed to this pathway. If FDA requires a traditional Phase 3 with clinical endpoints (lung function decline over 2-3 years), the timeline and cost multiply dramatically.

5. Arrowhead/Takeda is in Phase 3 for AATD liver disease — the same target as WVE-006. (10-K line 1510-1512.) This is the most advanced program for AATD liver pathology. If their drug succeeds first, WVE-006's commercial opportunity narrows significantly.

6. INHBE mechanism may not translate. Human heterozygous LoF carriers show metabolic benefits, but pharmacological knockdown to >50% silencing in adults with established obesity may produce different effects than lifelong partial loss of function.

Financial

7. Dilution is structural. With $188M/yr burn and no product revenue in sight before 2028-2029 at earliest, at least one more significant capital raise is required. Shares more than doubled in 3 years (86.9M to 187.7M). Further dilution of 20-40% over the next 2-3 years is plausible, depending on pipeline scope.

8. WVE-006 self-funding is a new, unfunded obligation. The cost to take WVE-006 from current Phase 1/2 through pivotal, registration, and commercialization is substantial (our estimate: $200-450M). This obligation transferred from GSK's balance sheet to Wave's as of February 2026.

9. GSK collaboration concentration risk. FY2025 revenue derived entirely from one counterparty. GSK can terminate on convenience, target-by-target, at any time. GSK has never mentioned Wave on an earnings call.

Governance/Structural

10. Singapore incorporation. PFIC risk for US holders if share price drops and passive assets dominate. IPOS Section 34 patent application violations pending resolution. Different shareholder rights framework than Delaware. (10-K lines 5872-5876, 5997-6001.)

11. SNBL related party payments. 4.6x increase ($1.0M to $4.6M) with no specific explanation in MD&A. Board member's company. (10-K lines 9460-9469.)

12. No insider open-market purchases. Management receives equity awards but has never bought shares voluntarily. Revealed preference.

VIII. WHAT TO WATCH

Near-Term Catalysts (2026)

Monitoring Metrics

• Cash burn trajectory: Is quarterly burn accelerating beyond $50M/quarter? When does the next raise become necessary?
• Deferred revenue recognition: Track quarterly revenue vs remaining deferred balance.
• GSK program selections: 4 of up to 8 programs selected. Pace indicates platform productivity.
• Insider Form 4 filings: Watch for code P (open market purchase). First voluntary buy would be meaningful.
• Arrowhead/Takeda AATD Phase 3 data: Direct competitive readthrough for WVE-006.
• INHBE competitor data: Arrowhead's dose-escalation data in particular — direct mechanism comparison.
• ATM usage: Jefferies ATM facility activity creates overhang; track quarterly.

SOURCES

All financial data verified against WVE 10-K filed February 26, 2026 (SEC EDGAR). Specific line references provided throughout. Pipeline and clinical data from 10-K Item 1 (lines 435-572 for INLIGHT, 574-623 for AATD, 674-715 for PNPLA3). Competition data from 10-K competition section (lines 1478-1569). GSK collaboration terms from 10-K Item 1 (lines 1231-1289) and Note 5 (lines 8615-8664). Revenue breakdown from 10-K MD&A (lines 6697-6709). Insider transactions from Form 4 filings (SEC EDGAR) and Schedule 13D/A (Dec 15, 2025). Factor regression from iev regress tool (1Y, 250 trading days, multi-factor model). These are our calculations. Market data and options from yfinance (Feb 26, 2026 close). Analyst estimates from stockanalysis.com consensus (16-17 analysts). BEAM competitive data from BEAM Q3 2024 earnings transcript. KRYS data from KRYS Q4 2025 and Q1 2025 earnings transcripts.

LR Signal: 1.05 — Approximately consensus. The market is pricing conservative but roughly appropriate probabilities for a clinical-stage platform with Phase 1 data. The INLIGHT obesity data (p=0.07 for total body fat, 0.9% total mass loss) is weaker than the narrative suggests, partially offsetting platform optionality. Options IV is cheap (14th %ile) ahead of Q1 catalysts, which is a genuine mispricing, but this is a vol observation not a directional one. The WVE-006 rights return shifts economics but also shifts costs — not clearly net positive at current price. 16/16 analyst Buy with zero dissent and 10.5% short interest suggests the consensus bullish view is fully reflected. The Q1 2026 data readouts are the swing variable; until they report, current price is approximately fair for the information available.